2016 Atrial Fibrillation Heart Failure 
DAIC
JULY 24, 2024
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrial fibrillation procedures. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
Frontiers in Cardiovascular Medicine
FEBRUARY 14, 2024
Background The impact of early rhythm control (ERC) combined with healthy lifestyle (HLS) on the risk of ischemic stroke in elderly patients with atrial fibrillation (AF) remains unaddressed. Objective To evaluate the impact of combined ERC and HLS on the risk of stroke in elderly patients with new-onset AF.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
European Journal of Heart Failure
NOVEMBER 3, 2023
Among 475 patients with cardiac sarcoidosis, 119 (25.1%) were isolated cardiac sarcoidosis (iCS) based on the 2016 Japanese Circulation Society criteria. iCS was diagnosed according to the 2016 Japanese Circulation Society (JCS) guidelines. Among 475 patients with CS (mean age, 62.0 ± 10.9 years; During a median follow-up of 42.3
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
IntroductionCardiomyopathy (CM) is a diverse pathology defined by both structural and functional changes in the heart. The National Inpatient Sample (NIS) database from 2016‐2019 for patients with a principal diagnosis of AIS using the ICD‐10 code I63 was queried. AIS patients with CM and HF were compared to those without.
Journal of the American Heart Association
MARCH 27, 2025
years]) admitted to the China Chest Pain Center Database between 2016 and 2021. Hierarchical clustering of 15 medical conditions was performed to derive multimorbidity patterns. The primary outcome was a composite of inhospital adverse events.
DAIC
JUNE 19, 2024
In July 2023 Eko Health announced a partnership with Japanese Life Sciences company Astellas Pharma to develop a non-invasive device Digital Therapeutics (DTx) solution for heart failure patients. In April 2022 BMS had received FDA approval for Camzyos, the first drug developed specifically for targeting HCM.
Expert insights. Personalized for you.
105 
Let's personalize your content